WCM
CORT icon

Wedge Capital Management’s Corcept Therapeutics CORT Stock Holding History

Wedge Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-55,523
Closed -$619K – 579
2019
Q2 		$619K Buy
55,523
+4,055
+8% +$45.2K 0.01% 426
2019
Q1 		$604K Buy
+51,468
New +$640K 0.01% 431

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wedge Capital Management's CORT Position: Q3 2019 in Review

Wedge Capital Management sold out of Corcept Therapeutics (CORT) in Q3 2019, closing a stake of 55,523 shares — an estimated $619K sold.

Wedge Capital Management first reported a position in CORT in Q1 2019 and held it in 2 quarters. The position peaked at $619K in Q2 2019. 193 funds tracked by Wall St. Rank hold CORT as of Q3 2019.

  • Wedge Capital Management reported no remaining Corcept Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Wedge Capital Management sold 55,523 Corcept Therapeutics shares in Q3 2019, an estimated $619K.
  • Wedge Capital Management first reported a position in Corcept Therapeutics in Q1 2019 and held it in 2 quarters.
  • Wedge Capital Management's Corcept Therapeutics position peaked at $619K in Q2 2019.
  • 193 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2019.

Based on Wedge Capital Management's 13F filing for Q3 2019, filed 1 Nov 2019.